Some biomarkers are based on the mutational status of genes known to be important in CRC carcinogenesis (NRAS, KRAS, BRAF) or associated with defects in the DNA mismatch repair system (MMR) (Table 1). This evidence concerns the gene BRAF and colorectal carcinoma.